Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxygen + nitrous oxide is a fixed-ratio combination medical gas, typically containing 50% nitrous oxide and 50% oxygen. It is administered via inhalation for its analgesic (pain-relieving) and anxiolytic (anxiety-reducing) effects. The mixture acts rapidly—onset within about 30 seconds—and the effects last for approximately one minute after cessation. Nitrous oxide functions primarily as an N-methyl-D-aspartate (NMDA) receptor antagonist in the central nervous system, producing dissociative anesthesia and analgesia while maintaining consciousness at sub-anesthetic doses. Oxygen ensures adequate tissue oxygenation during administration of nitrous oxide, which can otherwise displace atmospheric oxygen in the lungs. This combination is widely used for short-term pain relief during procedures such as childbirth, dental work, trauma care, and minor surgical interventions[5]. It is also used in emergency medicine settings due to its rapid onset and offset of action[5]. The product is supplied under various brand names such as Entonox or Nitronox[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oxygen + nitrous oxide.